CBC
Cannabichromene · CBC · Discovered 1966
Learn about CBC (Cannabichromene), a non-psychoactive cannabinoid with potent anti-inflammatory, antidepressant, and neurogenesis-promoting properties. Explore its unique mechanism of action and therapeutic potential.
Psychoactive
No
Discovered
1966
Effects
8 documented
Benefits
4 studied
Overview
Cannabichromene (CBC) is the third most abundant cannabinoid in cannabis, though it receives far less attention than THC or CBD. Discovered in 1966, CBC is derived from the same precursor as THC and CBD — cannabigerolic acid (CBGA) — which is converted by a specific enzyme (CBCA synthase) into cannabichromenic acid (CBCA), and then decarboxylated into CBC. Unlike many cannabinoids, CBC does not bind significantly to CB1 receptors in the brain and therefore produces no psychoactive effects.
CBC's therapeutic profile is distinguished by its potent anti-inflammatory properties and its remarkable ability to promote neurogenesis — the growth of new brain cells. A landmark 2013 study found that CBC enhanced the viability of adult neural stem progenitor cells, suggesting it may play a role in brain health and potentially in the treatment of neurodegenerative diseases. This neurogenesis-promoting effect, combined with its anti-inflammatory and antidepressant properties, makes CBC one of the most intriguing cannabinoids from a neurological research perspective.
Despite its abundance in the plant and promising preclinical data, CBC remains under-researched compared to THC and CBD, partly because it has not been the target of major drug development programs. However, the growing interest in minor cannabinoids is beginning to change this, with several research groups now investigating CBC's potential applications in pain management, depression, acne, and cancer.
Mechanism of Action
CBC does not bind significantly to CB1 or CB2 cannabinoid receptors. Instead, it exerts its effects primarily through interaction with transient receptor potential (TRP) channels. CBC is a potent agonist of TRPA1 (involved in pain and inflammation signaling) and TRPV1 (the capsaicin receptor, involved in pain perception and body temperature regulation). By activating these channels, CBC can desensitize them over time, potentially reducing pain sensitivity. CBC also inhibits the reuptake of the endocannabinoid anandamide, allowing it to remain active in the bloodstream longer and enhancing overall endocannabinoid tone. This mechanism is similar to CBD's FAAH inhibition and may contribute to mood regulation and anti-inflammatory effects. CBC also interacts with TRPV3 and TRPV4 channels, which are involved in skin health and inflammation, potentially explaining its reported benefits for acne and dermatological conditions.
Therapeutic Effects
Potential Benefits
Depression
Preclinical evidence. A 2010 study by El-Alfy et al. found CBC demonstrated significant antidepressant effects in rodent models, contributing to the 'entourage effect' of cannabis on mood. The effect may be mediated through enhanced anandamide signaling and TRPV1 activation.
Neurodegeneration
Preclinical evidence. A 2013 study by Shinjyo and Di Marzo found CBC promoted neurogenesis by enhancing the viability of neural stem progenitor cells (NSPCs). This could have implications for Alzheimer's, Parkinson's, and recovery from brain injuries.
Pain and Inflammation
Preclinical evidence. CBC has shown analgesic and anti-inflammatory effects through TRPA1 channel activation and anandamide reuptake inhibition. A 2012 study showed CBC reduced intestinal inflammation in a murine colitis model, working synergistically with THC.
Acne
Laboratory evidence. CBC has demonstrated powerful anti-acne properties by reducing sebaceous gland lipid production and exerting anti-inflammatory effects on sebocytes. Its activity at TRPV3 and TRPV4 channels in skin cells contributes to this effect.
Side Effects & Risks
- ⚠Very few side effects reported due to limited human studies
- ⚠Generally considered well-tolerated
- ⚠Potential for mild gastrointestinal effects
- ⚠Possible interactions with medications metabolized by cytochrome P450 enzymes
- ⚠Long-term safety profile not established in clinical trials
Concentration & Sources
Typical Concentration
0.1-1% in most cannabis flower; up to 3% in certain landrace and specialty cultivars; limited availability in isolated consumer products
Found In
Most cannabis cultivars in small amounts, with higher concentrations in landrace strains from tropical regions. Some specialty breeders are developing CBC-dominant cultivars. Available in limited CBC-specific tinctures and isolates.
Legal Status
Legal in the United States when derived from hemp. Not scheduled as a controlled substance. Legal in most jurisdictions as it is non-psychoactive and not specifically regulated.
Research Summary
CBC research, while limited compared to THC and CBD, has produced several notable findings. The 2013 neurogenesis study by Shinjyo and Di Marzo was a breakthrough, demonstrating that CBC could promote the growth of new neural cells — a finding with enormous potential implications for neurodegenerative disease treatment. Earlier work established CBC's potent anti-inflammatory effects, including a 2012 study showing synergistic anti-inflammatory action with THC in colitis models. CBC's antidepressant properties, identified in animal models, add to the evidence that the endocannabinoid system plays a crucial role in mood regulation. Dermatological research has revealed CBC's potential as an anti-acne treatment through sebocyte modulation. Despite these promising leads, CBC remains in the preclinical research phase, with no human clinical trials completed as of 2025. The development of CBC-enriched cannabis cultivars and isolated CBC products is expected to accelerate human research in the coming years.
Related Cannabinoids
CBC FAQ
What is CBC cannabinoid?
CBC (cannabichromene) is the third most abundant cannabinoid naturally produced in the cannabis plant. It is non-psychoactive, meaning it does not produce a high. CBC is synthesized from the same precursor (CBGA) as THC and CBD and is known for its anti-inflammatory, antidepressant, and neurogenesis-promoting properties. It primarily works through TRP channels and endocannabinoid reuptake inhibition rather than direct cannabinoid receptor binding.
Does CBC help with pain?
Preclinical research suggests CBC has analgesic (pain-relieving) properties. It works by activating TRPA1 and TRPV1 channels involved in pain signaling and by inhibiting the reuptake of the endocannabinoid anandamide, which plays a role in pain modulation. CBC has shown synergistic pain-relieving effects when combined with THC, contributing to the entourage effect. However, human clinical trials specifically testing CBC for pain have not been conducted.
Can CBC promote brain cell growth?
A 2013 study published by Shinjyo and Di Marzo found that CBC promoted the viability of adult neural stem progenitor cells (NSPCs), which are essential for brain neurogenesis — the growth of new neurons. These cells differentiated into astroglial cells important for brain homeostasis. This finding suggests CBC could potentially support brain health and may have applications in neurodegenerative disease research, though human studies are needed to confirm these effects.
Is CBC legal?
CBC is legal in the United States when derived from hemp containing less than 0.3% THC. It is not specifically listed as a controlled substance at the federal level. Because CBC is non-psychoactive and structurally distinct from THC, it falls outside most drug scheduling frameworks. However, regulations vary by state and country, so consumers should verify local laws before purchasing CBC products.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.